Ardelyx, Inc. (ARDX)
ARDXNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$2.95
+0.0700 (+2.43%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $736.52m
- P/E
- –
- EPS, last 4 quarters
- $-0.2200
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.84 to $8.40
- Average volume
- 4.47m
- Previous close
- $2.88
Analysts
8 coveringBuy8 buy, 0 hold, 0 sell
Targets a year out average $13.14, +345.4% from here
Earnings
next estimate $0.0300Next report
Dec 2025
-100.0%
Mar 2026
-15.4%
Jun 2026
-40.0%
Sep 2026
+100.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $125.22m | $94.47m | $120.88m | $127.66m |
| Gross profit | $114.37m | $89.66m | $115.12m | $123.12m |
| Operating income | $5.10m | -$32.79m | -$12.43m | $4.02m |
| Net income | -$407.0k | -$37.60m | -$16.72m | -$737.0k |
Last four quarters: revenue $468.22m, margin -11.8%, free cash flow –
News
8 latest- Ardelyx: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 5 days ago
- Ardelyx (ARDX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- What Ardelyx (ARDX) Said on Its Q3 Earnings CallMarketBeat · 6 days ago
- Ardelyx, Inc. Reports Third Quarter 2026 Financial ResultsFintel · 6 days ago
- Ardelyx (ARDX) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks · 6 days ago
- Ardelyx (ARDX) Reports Break-Even Earnings for Q3Zacks · 6 days ago
- Ardelyx Reports Reduced Healthcare Utilization Following IBSRELA Initiation At ACG 2026 RTTNews · Oct 12, 2026
- New Strong Sell Stocks for October 9thZacks · Oct 9, 2026
The company
Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA (tenapanor) and XPHOZAH (tenapanor). The company's pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with its partners to develop and commercialize its products outside of the United States.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- ardelyx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.